XML 40 R25.htm IDEA: XBRL DOCUMENT v3.25.1
ACQUISITIONS AND DIVESTITURES (Tables)
6 Months Ended
Apr. 30, 2025
Business Combination, Asset Acquisition, Transaction between Entities under Common Control, and Joint Venture Formation [Abstract]  
Business Combination, Recognized Asset Acquired and Liability Assumed
The following table summarizes the consideration transferred to acquire Ipackchem and the final valuation of identifiable assets acquired and liabilities assumed at the acquisition date:
(in millions)Amounts Recognized as of the Acquisition DateMeasurement Period AdjustmentsAmount Recognized as of Acquisition Date (as Adjusted)
Fair value of consideration transferred
Cash consideration$582.1 $— $582.1 
Recognized amounts of identifiable assets acquired and liabilities assumed
Cash and cash equivalents$14.5 $— $14.5 
Accounts receivable50.9 — 50.9 
Inventories36.7 — 36.7 
Other current assets4.9 (0.6)4.3 
Intangibles231.7 1.4 233.1 
Operating lease right-of-use assets15.1 2.4 17.5 
Finance lease right-of-use assets8.2 2.2 10.4 
Other long-term assets1.0 — 1.0 
Properties, plants and equipment91.5 (2.9)88.6 
Total assets acquired
454.5 2.5 457.0 
Accounts payable(17.2)— (17.2)
Short-term borrowings(26.2)— (26.2)
Other current liabilities(13.2)0.1 (13.1)
Operating lease liabilities(14.2)(3.3)(17.5)
Finance lease liabilities(10.0)(0.5)(10.5)
Long-term deferred tax liability(62.1)(1.5)(63.6)
Other long-term liabilities(5.3)(2.5)(7.8)
Total liabilities assumed
(148.2)(7.7)(155.9)
Total identifiable net assets$306.3 (5.2)301.1 
Goodwill$275.8 $5.2 $281.0 
Business Combination, Intangible Asset, Acquired, Finite-Lived The following table summarizes the final purchase price allocation and weighted average remaining useful lives for identifiable intangible assets acquired as of the acquisition date:
(in millions)Purchase Price AllocationWeighted Average Estimated Useful Life
Customer relationships$183.8 13.5
Developed technology39.0 8.0
Trademarks10.3 5.0
Total intangible assets$233.1 
Schedule of Business Acquisition, Pro Forma Information
The following unaudited supplemental pro forma data presents consolidated information as if the Ipackchem Acquisition had been completed on November 1, 2022. These amounts were calculated after adjusting Ipackchem’s results to reflect interest expense incurred on the debt to finance the acquisition, additional depreciation and amortization that would have been charged assuming the fair value of property, plant and equipment and intangible assets had been applied from November 1, 2022, the adjusted income tax expense, and related transaction costs.
Three Months Ended
April 30,
Six Months Ended
April 30,
(in millions, except per share amounts)20242024
Pro forma net sales$1,404.3 $2,665.7 
Pro forma net income attributable to Greif, Inc.54.6 130.2 
Basic earnings per share attributable to Greif, Inc. common shareholders:
Class A common stock$0.94 $2.26 
Class B common stock$1.42 $3.38 
Diluted earnings per share attributable to Greif, Inc. common shareholders:
Class A common stock$0.94 $2.26 
Class B common stock$1.42 $3.38